Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies By: CNBC.com News February 13, 2024 at 07:03 AM EST The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval. Read More >> Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies By: CNBC.com News February 13, 2024 at 07:03 AM EST The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval. Read More >>